High antibody titers of anti–citrullinated peptide antibodies, rheumatoid factor, and certain baseline factors predict RA ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable ...

Extraintestinal manifestations and arthralgia are significant predictors of IBD-related arthritis among patients with CD, while sacroiliitis was not associated.

Cycle Pharmaceuticals Limited (Cycle) announced today the launch of VENXXIVA (tiopronin) Delayed-Release Tablets, for the treatment of cystinuria, approved by the US Food and Drug Administration (FDA) ...

U.S. FDA approved EmrosiTM (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the tr ...

Bhopal: Health authorities in Bhopal have intensified their monitoring and preventive efforts following a roughly 10% rise in chikungunya incidents du.

The most common adverse events in the dupilumab group (occurring in at least three patients) included peripheral edema, arthralgia, back pain, blurred vision, hypertension, asthma, conjunctivitis ...